Hair Loss Glossary Terms Explained: The Patient-First Reference Guide

Introduction: Why Hair Loss Terminology Matters

For many people, the first encounter with hair loss terminology happens at the worst possible moment. During a consultation or a late-night online search, unfamiliar words like “androgenetic alopecia,” “miniaturization,” or “follicular unit extraction” begin appearing, and the experience can feel overwhelming and disempowering. Understanding the language is the first step toward regaining a sense of control.

Hair loss is one of the most common medical concerns people face. Approximately 85% of men and 33% of women experience some form of hair loss during their lifetime. By age 50, roughly 50% of men and 40% of women worldwide notice thinning. With numbers like these, clear and accessible information is not a luxury; it is a necessity.

This guide is not a dry alphabetical list. It is a patient-first reference organized by how and when patients actually encounter these terms, across five categories: foundational biology, diagnosis and assessment, types of hair loss, medical treatments, and surgical procedures. It also addresses the emerging and psychological dimensions that most glossaries ignore.

What makes this reference different: plain-language definitions, real-world analogies, “what to ask your doctor” prompts, and inclusion of 2024 through 2026 terminology that most competitors have not addressed. This includes JAK inhibitor approvals, clascoterone Phase 3 data, and the 2025 FDA safety updates for finasteride. Readers may move through it from start to finish or jump directly to the category most relevant to their current stage of the journey.

Part 1: Understanding Hair Loss — Foundational Biology Terms

Understanding the biology behind hair loss helps patients make sense of every diagnosis and treatment recommendation they receive. These foundational terms underpin everything else in this guide.

The Hair Growth Cycle: Anagen, Catagen, Telogen, and Exogen

Every hair on the scalp cycles through distinct phases:

• Anagen (growth phase): The active growth period, lasting 2 to 7 years. Roughly 85 to 90% of scalp hairs are in this phase at any given time.
• Catagen (transition phase): A brief 2 to 3 week phase in which the follicle shrinks and detaches from its blood supply.
• Telogen (resting phase): A 3-month resting period. Shedding 50 to 100 hairs per day is normal precisely because those hairs are in telogen, not because something is wrong.
• Exogen (shedding phase): The active release of the telogen hair as a new anagen hair pushes it out. This is a distinct fourth phase not always mentioned in standard references.

Real-world analogy: Think of a garden. Anagen is the growing season, catagen is the harvest, telogen is dormant winter, and exogen is clearing the old growth to make room for new.

Why it matters: This cycle explains why treatments take 3 to 6 months to show results and up to 9 to 12 months for noticeable improvement. The follicle must complete a cycle before new growth becomes visible.

What to ask your doctor: “Based on my hair loss pattern, which phase is most affected, and how does that influence the treatment timeline?”

Hair Follicle and Follicular Unit

The hair follicle is the living structure beneath the scalp that produces a hair shaft; it is the fundamental biological unit of hair growth. A follicular unit is a naturally occurring group of 1 to 4 hairs that share a common sebaceous gland, nerve, and blood supply. This is the unit used in modern hair transplantation.

An adult scalp typically contains 80,000 to 120,000 hairs.

Real-world analogy: A follicular unit is like a small apartment building. Multiple residents (hairs) share common infrastructure (blood supply, oil gland).

Why it matters: When a surgeon quotes a graft number, they are referring to follicular units, not individual hairs. A single graft may contain 1 to 4 hairs.

DHT (Dihydrotestosterone) and Androgenetic Alopecia

DHT is a potent androgen hormone derived from testosterone via the enzyme 5-alpha reductase, and it is the primary hormonal driver of androgenetic alopecia. DHT levels are approximately 5 times higher in balding scalps than in non-balding scalps.

Androgenetic alopecia (AGA) is the medical term for male or female pattern baldness, accounting for approximately 95% of all male hair loss cases. The word “androgenetic” reflects both the hormonal and genetic components. Genetic predisposition accounts for roughly 80% of male pattern baldness risk, with over 200 genetic loci identified.

Miniaturization is the process by which DHT causes follicles to progressively shrink, producing thinner, shorter hairs over time until the follicle stops producing hair entirely.

Real-world analogy: Miniaturization is like a plant slowly deprived of water. Growth becomes weaker and shorter each cycle until it stops.

Why it matters: Most medical treatments for pattern hair loss work by blocking DHT or its effects.

What to ask your doctor: “Is my hair loss DHT-driven, and if so, am I a candidate for DHT-blocking therapy?”

Donor Dominance

Donor dominance is the principle that transplanted hair retains the genetic characteristics of its donor site, not the recipient site. First described by Dr. Norman Orentreich in the 1950s, this discovery is the scientific foundation of all modern hair transplantation.

Real-world analogy: Like transplanting a drought-resistant plant from one part of a garden to another, it keeps its drought-resistant properties regardless of where it is planted.

Why it matters: Donor dominance is the reason transplants produce permanent results. The transplanted follicles retain their genetic programming regardless of their new location.

Part 2: Diagnosis and Assessment Terms

Before any treatment is recommended, a physician must assess the type, pattern, and severity of hair loss. Many of these terms arise during a first consultation, and understanding them helps patients participate more actively in their own care.

Hair Loss Classification Scales: Norwood, Ludwig, and Savin

The Norwood Scale (Hamilton-Norwood Scale) is the standard classification for male pattern baldness, ranging from Type I (minimal recession) to Type VII (most extensive loss). The Ludwig Scale is the primary classification for female pattern hair loss, with three grades reflecting progressive diffuse thinning at the crown while the frontal hairline is often preserved. The Savin Scale is a complementary scale for women that also captures overall thinning not reflected by the Ludwig Scale.

Why it matters: Knowing one’s grade helps clarify where a patient is in the progression and which options are appropriate.

What to ask your doctor: “What is my current Norwood or Ludwig grade, and based on my family history, what grade am I likely to progress to without treatment?”

Notably, ISHRS 2025 data shows 95% of first-time surgical patients in 2024 were aged 20 to 35, making early classification increasingly important for younger patients considering hair transplant options.

SALT Score (Severity of Alopecia Tool)

The SALT score is a standardized measurement used specifically for alopecia areata, quantifying the percentage of scalp hair loss on a scale of 0 (no loss) to 100 (complete loss). It is the primary endpoint in clinical trials for alopecia areata treatments, including the pivotal JAK inhibitor trials. A SALT score of 20 or lower (meaning 80% or more scalp coverage) is often used as a benchmark for treatment success.

What to ask your doctor: “What is my current SALT score, and what score would indicate a meaningful response to treatment?”

Trichoscopy and Dermoscopy

Dermoscopy is a non-invasive technique using a handheld magnifying device with a light source to examine skin and hair structures invisible to the naked eye. Trichoscopy is the application of dermoscopy specifically to the scalp and hair. Hair shaft diameter diversity greater than 20% is diagnostic of androgenetic alopecia on trichoscopy, a specific and measurable finding. Trichoscopy can also identify empty follicles in telogen effluvium, yellow dots in alopecia areata, and perifollicular scaling in scarring alopecias.

Real-world analogy: Trichoscopy is like using a magnifying glass to read the fine print on a contract.

What to ask your doctor: “Will trichoscopy be used in my evaluation, and what specific findings will you be looking for?”

Pull Test, Trichogram, and Hair Density Assessment

The pull test is a simple clinical test in which the physician grasps 40 to 60 hairs and gently pulls. Extracting more than 6 hairs is a positive result indicating active shedding. A trichogram is a microscopic analysis of plucked hairs to assess the ratio of anagen to telogen hairs. Hair density assessment measures follicular units per square centimeter, with normal density around 65 to 85 follicular units per cm². Densitometry is a more precise, often digital tool used to measure density and shaft diameter for tracking treatment response.

Why it matters: These tests provide objective data and establish a baseline against which progress can be measured.

Scalp Biopsy and Histopathology

A scalp biopsy removes a small tissue sample for microscopic examination and is the definitive diagnostic tool when the cause of hair loss is unclear. Histopathology is that microscopic examination, which can distinguish scarring from non-scarring alopecia and confirm specific diagnoses.

Why it matters: A biopsy is not routine for straightforward AGA but is essential for diagnosing scarring alopecias or unusual presentations.

Part 3: Types of Hair Loss — Conditions and Diagnoses

One distinction fundamentally determines what treatments are possible: scarring versus non-scarring alopecia.

Scarring vs. Non-Scarring Alopecia: The Most Important Distinction

In non-scarring alopecia, the follicle is damaged or dormant but not permanently destroyed, so regrowth is possible with appropriate treatment. Examples include androgenetic alopecia, alopecia areata, and telogen effluvium. In scarring alopecia (cicatricial alopecia), the follicle is permanently destroyed and replaced by scar tissue, so regrowth is not possible; treatment focuses on halting progression.

Real-world analogy: Non-scarring alopecia is like a dormant seed that can still grow under the right conditions. Scarring alopecia is like concrete poured over the soil.

What to ask your doctor: “Is my hair loss scarring or non-scarring, and what does that mean for my treatment options?”

Alopecia Areata

Alopecia areata is an autoimmune condition in which the immune system mistakenly attacks hair follicles, causing patchy loss. It affects roughly 1 in 1,000 people worldwide. Variants include alopecia totalis (complete scalp loss) and alopecia universalis (complete body loss). Because it is non-scarring, both spontaneous and treatment-induced regrowth are possible. The psychological impact is significant, particularly for adolescents and young adults.

Why it matters: This is the condition for which JAK inhibitors have been approved.

Telogen Effluvium

Telogen effluvium is diffuse, temporary shedding occurring 2 to 3 months after a physiological or psychological stressor such as illness, surgery, childbirth, or severe stress. It is the second most common form of hair loss after AGA and can affect 35 to 70% of scalp hairs simultaneously. Acute cases resolve within 6 months once the trigger is removed; chronic cases persist beyond 6 months.

Real-world analogy: Like a power surge tripping circuit breakers, many follicles simultaneously enter the resting phase.

What to ask your doctor: “Could my shedding be telogen effluvium, and if so, what was the likely trigger?”

Frontal Fibrosing Alopecia and Lichen Planopilaris

Frontal fibrosing alopecia (FFA) is a scarring alopecia characterized by progressive recession of the frontal hairline and loss of eyebrows. Its incidence has risen 3-fold over the last 20 years among postmenopausal women. Lichen planopilaris (LPP) is a scarring alopecia caused by follicular inflammation, presenting with patchy loss, itching, and burning. Both are cicatricial, so treatment focuses on halting progression.

Why it matters: FFA is increasingly common yet often misdiagnosed as simple hairline recession. Early diagnosis is critical.

CCCA (Central Centrifugal Cicatricial Alopecia) and Traction Alopecia

CCCA is a scarring alopecia that begins at the crown and spreads outward, disproportionately affecting Black women. Traction alopecia is caused by chronic tension from tight hairstyles such as braids, weaves, and ponytails. Initially non-scarring, it can become permanent if tension persists. These conditions are significantly underrepresented in most glossaries despite their prevalence.

What to ask your doctor: “Could my hair loss pattern be related to CCCA or traction, and what styling changes would help?”

For patients dealing with tension-related loss, our traction alopecia hair restoration guide provides a detailed overview of diagnosis and treatment options.

Part 4: Medical Treatment Terms

This section covers non-surgical options, from established medications to emerging therapies. Results typically require 3 to 6 months of treatment, and up to 9 to 12 months for noticeable improvement.

Minoxidil (Topical and Oral)

Minoxidil is a vasodilator originally developed as a blood pressure medication and later found to stimulate hair growth. It extends the anagen phase and increases blood flow to the follicle. Topical minoxidil (2% and 5%) has been FDA-approved for decades, and low-dose oral minoxidil has emerged as a significant clinical development. Combination therapy with oral minoxidil and finasteride has become the 2026 clinical gold standard, with a real-world UK study showing 92.4% of 502 patients achieving stable or improved outcomes over 12 months.

Why it matters: Minoxidil is a maintenance medication. Stopping it typically results in loss of any regrowth within 3 to 6 months.

What to ask your doctor: “Would topical or oral minoxidil be more appropriate for me, and what side effects should I watch for?”

Finasteride and 5-Alpha Reductase Inhibitors

Finasteride is an FDA-approved oral medication that inhibits 5-alpha reductase, reducing serum DHT by roughly 65 to 70%. Dutasteride blocks both Type I and Type II 5-alpha reductase and is used off-label in some cases. Search interest in finasteride rose 88% between 2020 and 2025. In October 2025, the FDA issued updated warnings regarding potential links to depression and mood changes, and the EMA updated labeling regarding suicidal ideation risk. Post-finasteride syndrome is a term some patients use to describe persistent side effects reported after discontinuation, an area of ongoing research.

What to ask your doctor: “Given the 2025 FDA warnings, am I an appropriate candidate for finasteride, and what monitoring would be in place?”

Patients curious about treatment timelines may find it helpful to read about why finasteride might take longer to work before drawing conclusions about its effectiveness.

JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib

JAK inhibitors (Janus kinase inhibitors) block enzymes involved in the inflammatory signaling that drives the autoimmune follicle attack in alopecia areata. Three have received FDA approval for severe alopecia areata: baricitinib (Olumiant, 2022), ritlecitinib (Litfulo, 2023), and deuruxolitinib (Leqselvi, 2024). Together, these approvals represent the most significant pharmacological advance in autoimmune hair loss in a decade. Importantly, they are approved for alopecia areata specifically, not androgenetic alopecia.

Real-world analogy: JAK inhibitors act like a cease-fire signal, interrupting the message that tells immune cells to attack follicles.

What to ask your doctor: “Am I a candidate for a JAK inhibitor, and which one would be most appropriate for my severity and medical history?”

Clascoterone: An Emerging Topical Anti-Androgen

Clascoterone is a topical androgen receptor antagonist that blocks DHT from binding to receptors in the scalp without the systemic effects of oral anti-androgens. Phase 3 trial data from December 2025 demonstrated up to 539% relative improvement in hair count versus placebo for the 5% solution, with FDA submission expected in 2026. If approved, it would represent the first new mechanism of action in AGA treatment in over 30 years.

What to ask your doctor: “Is clascoterone available or in trials I might qualify for, and how does it compare to existing options?”

PRP (Platelet-Rich Plasma) and Regenerative Therapies

PRP is derived from the patient’s own blood, centrifuged to concentrate growth factors that are then injected into the scalp to stimulate follicle activity. Exosomes and secretome therapy are emerging approaches using cell-derived signaling molecules. Microneedling with PRP combines micro-channels with PRP to enhance absorption.

Why it matters: Regenerative therapies work with the body’s own biology and typically complement rather than replace other treatments.

For a detailed breakdown of what this treatment involves and what it costs, see our overview of platelet-rich plasma hair loss treatment.

Low-Level Laser Therapy (LLLT) and FDA Approval vs. Clearance

LLLT uses specific light wavelengths to stimulate cellular activity in follicles, delivered via caps, combs, or in-office devices. A critical distinction: pharmacologic agents like minoxidil and finasteride are FDA-approved (meaning the FDA reviewed clinical evidence of safety and efficacy), while LLLT devices are FDA-cleared (deemed substantially equivalent to a legally marketed device, a safety standard rather than an efficacy review).

Real-world analogy: Approval is like a recipe certified by a culinary institute. Clearance is like a kitchen appliance certified as safe to use, without any review of whether it produces better food.

What to ask your doctor: “Is this treatment FDA-approved or FDA-cleared, and what does that mean for the evidence behind its effectiveness?”

Part 5: Surgical Hair Restoration Terms

Surgical restoration has its own vocabulary. Understanding these terms helps patients ask better questions and set realistic expectations.

FUE (Follicular Unit Extraction)

FUE extracts individual follicular units one at a time from the donor area using a small circular punch (typically 0.7 to 1.0 mm) and transplants them to the recipient area. It leaves no linear scar and offers faster recovery. Robotic-assisted FUE with AI-driven planning has become an increasingly common surgical approach, offering precision extraction and consistent graft quality.

Real-world analogy: FUE is like transplanting individual seedlings one by one.

What to ask your doctor: “Am I a better candidate for FUE or FUT, and what factors influence that recommendation?”

FUT (Follicular Unit Transplantation / Strip Surgery)

FUT removes a strip of scalp tissue from the donor area, dissects it under microscopes into follicular units, and transplants them. Also called microscopic strip surgery, it leaves a linear scar typically concealed by surrounding hair. FUT allows larger graft sessions and is often well-suited for certain female patients. FUE and FUT can also be combined to maximize total graft yield for patients requiring larger sessions.

Real-world analogy: FUT is like harvesting an entire garden row, then separating and replanting each plant.

Why it matters: FUE and FUT are complementary, not competing, techniques. Patients weighing their options can explore the difference between FUE and FUT hair restoration in greater detail.

Donor Area, Recipient Area, and the Safe Donor Zone

The donor area (typically the back and sides of the scalp) supplies follicles that are genetically DHT-resistant. The recipient area is where those follicles are placed. The safe donor zone is the specific region where follicles are reliably DHT-resistant.

Why it matters: The size and density of the safe donor zone determine how many grafts can be harvested over a lifetime, which is why a thorough donor assessment is essential before any surgical plan is finalized.

Graft, Graft Survival, and Hair Yield

A graft is a prepared follicular unit containing 1 to 4 hairs. Graft survival rate is the percentage of transplanted grafts that establish a blood supply and continue to grow. Hair yield is the total number of hairs transplanted, which differs from graft count.

What to ask your doctor: “What is your typical graft survival rate, and how many hairs per graft do you expect for my hair type?”

Hairline Design, Density, and Naturalness

Hairline design is the artistic and technical planning of graft placement, taking into account facial proportions, age-appropriate recession, and future progression. Density refers to grafts or hairs per square centimeter. Angulation and direction describe the angle at which each graft is placed, which is critical for achieving natural flow.

Why it matters: Surgical artistry is as important as technical skill in producing a natural result. Learn more about the principles behind hairline design in hair transplant surgery and what separates a natural-looking outcome from an obvious one.

SMP (Scalp Micropigmentation)

SMP deposits specialized pigment into the scalp using micro-needles to replicate the appearance of follicles or add visual density. It can stand alone for non-surgical candidates, camouflage transplant scars, or enhance thinning areas. It is not a hair growth treatment.

Why it matters: SMP can be a powerful complement to surgical or medical treatment. For patients considering this option, our guide on SMP for thinning hair covers candidacy, process, and what to expect.

Part 6: Emerging and Pipeline Therapy Terms (2024–2026)

These terms increasingly appear in news coverage and specialist consultations. “Emerging” does not mean unproven; some of these therapies carry significant clinical data.

PROTAC Technology (Proteolysis Targeting Chimeras)

PROTAC uses bifunctional molecules to selectively degrade specific proteins. In the context of hair loss, these molecules are designed to degrade the androgen receptor specifically in scalp follicles. Early-phase 2025 to 2026 trial data suggests this approach may offer anti-androgenic benefits without systemic hormonal effects.

Real-world analogy: If finasteride turns down the volume throughout a building, PROTAC aims to mute only the specific problem speaker.

What to ask your doctor: “Are there any PROTAC trials I might qualify for, and when might this be available clinically?”

Combination Therapy and the 2026 Clinical Standard

Combination therapy uses two or more treatments with complementary mechanisms, such as oral minoxidil (extending anagen) paired with finasteride (reducing DHT). A UK study showing 92.4% of 502 patients achieving stable or improved outcomes over 12 months has established this approach as the 2026 clinical gold standard for AGA. For a comprehensive look at where these treatments stand today, see our overview of androgenetic alopecia treatment in 2026.

What to ask your doctor: “Would a combination approach be appropriate for me, and how would we monitor for side effects?”

Exosomes and Secretome Therapy

Exosomes are nano-sized vesicles secreted by cells that carry growth factors, proteins, and genetic material. Secretome therapy is a broader term for treatments using the full array of bioactive molecules secreted by cells. Both represent a next generation of regenerative medicine beyond traditional PRP.

Why it matters: Understanding these therapies helps patients evaluate whether the available evidence supports their use for a specific condition.

Part 7: Psychological and Quality-of-Life Terms

Hair loss is not only a medical condition. It has well-documented psychological dimensions that most competitor glossaries ignore, leaving patients without language to discuss the emotional impact.

Psychological Impact of Hair Loss and Quality of Life

Hair loss significantly affects self-esteem, body image, social functioning, and psychological well-being, particularly for women and young adults. A recognized clinical practice gap is the underestimation of this impact; patients often feel their distress is dismissed. Alopecia areata carries a particular psychological burden for adolescents and young adults.

What to ask your doctor: “Are there resources or referrals for the psychological aspects of hair loss, and how do you factor quality of life into treatment planning?”

Body Dysmorphic Disorder (BDD) in the Context of Hair Loss

Body dysmorphic disorder (BDD) is a mental health condition characterized by obsessive preoccupation with a perceived flaw that others cannot see or consider minor. BDD is an important consideration in surgical candidacy because affected patients may not achieve satisfaction regardless of the technical result. Responsible practices screen for BDD as part of the consultation process.

Why it matters: A consultation that includes psychological assessment is a sign of a responsible practice, not an obstacle.

The HairFirst Patient Behavior Framework

HairFirst Groups is a framework published in peer-reviewed literature in 2025 describing patients who prioritize hair preservation above conventional medical recommendations, such as avoiding medications with hair loss side effects even when those medications are otherwise indicated.

Why it matters: Naming this dynamic helps patients have more productive conversations with all of their healthcare providers.

Part 8: Quick-Reference Glossary — Alphabetical Index of Key Terms

• Alopecia areata: Autoimmune patchy hair loss (Part 3).
• Anagen: Active hair growth phase (Part 1).
• Androgenetic alopecia: Male or female pattern baldness (Part 1).
• Baricitinib: FDA-approved JAK inhibitor for alopecia areata (Part 4).
• CCCA: Scarring alopecia beginning at the crown (Part 3).
• Catagen: Brief follicle transition phase (Part 1).
• Clascoterone: Topical anti-androgen in Phase 3 development (Part 4).
• Densitometry: Precise measurement of hair density and shaft diameter (Part 2).
• Dermoscopy: Magnified skin and hair examination (Part 2).
• Deuruxolitinib: FDA-approved JAK inhibitor (Part 4).
• DHT: Hormone driving pattern baldness (Part 1).
• Donor area: Region supplying transplant follicles (Part 5).
• Donor dominance: Transplanted hair retains its donor characteristics (Part 1).
• Dutasteride: 5-alpha reductase inhibitor used off-label (Part 4).
• Exogen: Active shedding phase (Part 1).
• Exosomes: Cell-derived regenerative vesicles (Part 6).
• FDA approval vs. clearance: Efficacy review versus safety equivalence (Part 4).
• Finasteride: DHT-reducing oral medication (Part 4).
• FUE: Individual follicular unit extraction (Part 5).
• FUT: Strip harvesting technique (Part 5).
• Graft: Prepared follicular unit of 1 to 4 hairs (Part 5).
• JAK inhibitor: Medication class for alopecia areata (Part 4).
• Lichen planopilaris: Inflammatory scarring alopecia (Part 3).
• LLLT: Low-level laser therapy (Part 4).
• Ludwig Scale: Female pattern loss classification (Part 2).
• Miniaturization: Progressive follicle shrinkage (Part 1).
• Minoxidil: Growth-stimulating vasodilator (Part 4).
• Norwood Scale: Male pattern loss classification (Part 2).
• PRP: Platelet-rich plasma injection therapy (Part 4).
• PROTAC: Emerging androgen-receptor-degrading technology (Part 6).
• Pull test: Clinical shedding assessment (Part 2).
• Recipient area: Where follicles are transplanted (Part 5).
• Ritlecitinib: FDA-approved JAK inhibitor (Part 4).
• Safe donor zone: Reliably DHT-resistant harvest region (Part 5).
• SALT score: Alopecia areata severity measure (Part 2).
• Scarring alopecia: Permanent follicle destruction (Part 3).
• Secretome therapy: Bioactive molecule regenerative treatment (Part 6).
• SMP: Scalp micropigmentation (Part 5).
• Telogen: Resting hair phase (Part 1).
• Telogen effluvium: Diffuse stress-triggered shedding (Part 3).
• Traction alopecia: Tension-induced hair loss (Part 3).
• Trichogram: Microscopic analysis of plucked hairs (Part 2).
• Trichoscopy: Scalp dermoscopy (Part 2).

Conclusion: From Terminology to Informed Action

Understanding the language of hair loss is the first step toward becoming an active, informed participant in one’s own care rather than a passive recipient of recommendations that are not fully understood. Every term a patient learns is a tool for better communication with their medical team.

A few distinctions matter most: scarring versus non-scarring alopecia, FDA approval versus clearance, graft count versus hair yield, and the difference between treating androgenetic alopecia versus alopecia areata. Hair loss is generally easier to address when caught early, so this terminology is most useful when applied sooner rather than later.

The field is evolving rapidly. The 2022 through 2026 period has delivered more pharmacological advances than the preceding three decades, making this an important time to be an informed patient. No glossary, however, replaces a personalized consultation. The terms here provide context, but a patient’s specific diagnosis, hair characteristics, and medical history determine which options are appropriate.

Take the Next Step: Schedule a Consultation with Shapiro Medical Group

For patients ready to move from research to a personalized evaluation, Shapiro Medical Group offers a trusted resource. The practice has focused exclusively on hair restoration since 1990. Dr. Ron Shapiro co-authored the leading medical textbook on hair transplantation, and the team has lectured at over 100 conferences in more than 20 countries.

Shapiro Medical Group’s one-patient-per-day policy is a direct expression of the patient-first philosophy that also shaped this glossary. Every patient receives the full, undivided attention of the medical team. The practice serves patients locally in Minneapolis, throughout the United States, and internationally, with established protocols for those traveling from out of state or abroad.

Patients are encouraged to bring their questions, including the “what to ask your doctor” prompts throughout this guide, to their consultation. To receive a personalized evaluation from a team that has dedicated over three decades exclusively to hair restoration, schedule a consultation through the Shapiro Medical Group website.